Literature DB >> 10726657

The roles of E6-AP and MDM2 in p53 regulation in human papillomavirus-positive cervical cancer cells.

M Traidej1, L Chen, D Yu, S Agrawal, J Chen.   

Abstract

The p53 tumor suppressor is regulated by the MDM2 oncoprotein through a negative feedback mechanism. MDM2 promotes the ubiquitination and proteasome-dependent degradation of p53, possibly by acting as a ubiquitin ligase. In cervical cancer cells containing high-risk human papillomaviruses (HPV), p53 is also targeted for degradation by the HPV E6 oncoprotein in combination with the cellular E6-AP ubiquitin ligase. In this report, we describe the identification of efficient antisense oligonucleotides against human E6-AP. The roles of MDM2 and E6-AP in p53 regulation were investigated using a novel E6-AP antisense oligonucleotide and a previously characterized MDM2 antisense oligonucleotide. In HPV16-positive and HPV-18 positive cervical cancer cells, inhibition of E6-AP, but not MDM2, expression results in significant induction of p53. In HPV-negative tumor cells, p53 is activated by inhibition of MDM2 but not E6-AP. Furthermore, treatment with both E6-AP and MDM2 antisense oligonucleotides in HPV-positive cells does not lead to further induction of p53 over inhibition of E6-AP alone. Therefore, E6-AP-mediated degradation is dominant over MDM2 in cervical cancer cells but does not have a significant role in HPV-negative cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10726657     DOI: 10.1089/oli.1.2000.10.17

Source DB:  PubMed          Journal:  Antisense Nucleic Acid Drug Dev        ISSN: 1087-2906


  6 in total

1.  A DHX9-lncRNA-MDM2 interaction regulates cell invasion and angiogenesis of cervical cancer.

Authors:  Xiangya Ding; Xuemei Jia; Cong Wang; Jingyun Xu; Shou-Jiang Gao; Chun Lu
Journal:  Cell Death Differ       Date:  2018-12-05       Impact factor: 15.828

2.  A genetic variant within MDM4 3'UTR miRNA binding site is associated with HPV16-positive tumors and survival of oropharyngeal cancer.

Authors:  Yang Zhang; Erich M Sturgis; Peng Wei; Hongliang Liu; Ziqiao Wang; Yiding Ma; Chuan Liu; Kyle J Gu; Qingyi Wei; Guojun Li
Journal:  Mol Carcinog       Date:  2019-09-12       Impact factor: 4.784

3.  HPV16 E6 confers p53-dependent and p53-independent phenotypes in the epidermis of mice deficient for E6AP.

Authors:  A Shai; M L Nguyen; J Wagstaff; Y-H Jiang; P F Lambert
Journal:  Oncogene       Date:  2006-11-27       Impact factor: 9.867

Review 4.  From bortezomib to other inhibitors of the proteasome and beyond.

Authors:  Daniela Buac; Min Shen; Sara Schmitt; Fathima Rani Kona; Rahul Deshmukh; Zhen Zhang; Christine Neslund-Dudas; Bharati Mitra; Q Ping Dou
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

5.  Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells.

Authors:  A Hengstermann; L K Linares; A Ciechanover; N J Whitaker; M Scheffner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-23       Impact factor: 11.205

6.  Knockdown of RNF6 inhibits HeLa cervical cancer cell growth via suppression of MAPK/ERK signaling.

Authors:  Kang Zhu; He Bai; Mingzhu Mu; Yuanyuan Xue; Zhao Duan
Journal:  FEBS Open Bio       Date:  2021-06-18       Impact factor: 2.792

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.